Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis

The disease affects approximately 25,000 people in the UK, the majority of whom are women

- PMLiVE

Unlocking potential: key life sciences priorities for the Autumn Budget

By Ahmed Moussa

- PMLiVE

Investment and impact: navigating the complexities of a European launch

By Hristo Deyanov

- PMLiVE

What is health literacy, and why should it matter to us?

Dr Alexandra Loveday explores the concept of health literacy and why it matters so much when crafting comms and medical education materials aimed at patients.

Mednet

- PMLiVE

Merck’s Keytruda recommended by NICE to reduce risk of lung cancer recurrence

More than 5,000 patients in England are expected to be eligible for the anti-PD-1 therapy

- PMLiVE

AstraZeneca/Ionis’ Wainzua receives positive CHMP opinion to treat rare disease ATTRv-PN

The drug can be self-administered via an auto-injector and is designed to lower the production of TTR protein at its source

- PMLiVE

Inizio Medical appoints Patrick Giordani as senior vice president, AI solutions architect

Giordani most recently served as vice president of data at Kiwi.com

- PMLiVE

The make-or-break moment for your biopharma product success

By Sheila Reddy

- PMLiVE

Age is not just a number when it comes to clinical trials

In this blog we look at the critical underrepresentation of older adults in clinical trials, emphasising the need for inclusive trial designs and targeted strategies to ensure safe and effective...

Cuttsy + Cuttsy

- PMLiVE

Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment

Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year

- PMLiVE

Novo Nordisk’s Alhemo recommended by CHMP for haemophilia A and B

The rare bleeding disorder affects approximately 1,125,000 people globally

- PMLiVE

Optimising MSL impact in clinical trials: addressing the industry’s diversity challenge

By Jeff Vaughan

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links